Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

208
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
208
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

127
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
127
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

135
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
135
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

152
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
152
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

96
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
96
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

250
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
250

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioenergetic benefits and therapeutic potential of storable mitochondria.

Biochemical and biophysical research communications·2026
Same author

Targeted Intracellular Delivery of Amino Acids to Trophoblast Cells Reveals Proteomic Signatures of Cellular Utilisation.

Biomolecules·2026
Same author

Effect of vascular disrupting therapy by lipid nanoparticles on the tumor microenvironment.

International journal of pharmaceutics·2026
Same author

Lipid nanoparticles containing zwitterionic lipids versatilely enhance the efficiency of mRNA delivery.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Mitochondria-targeted coenzyme Q<sub>10</sub> nanocarriers evaluated by particle size and lipid composition alleviate early acetaminophen-induced liver injury.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Mitochondrial Activation and Therapeutics: Innovations in Cell- and Organelle-Specific Medicine.

Biological & pharmaceutical bulletin·2025

Related Experiment Video

Updated: Mar 28, 2026

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis
08:15

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis

Published on: February 3, 2022

3.7K

[Mitochondrial DDS Opens Innovative Pharmaceutics].

Yuma Yamada1

  • 1Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|January 5, 2016
PubMed
Summary
This summary is machine-generated.

Mitochondrial dysfunction is linked to many diseases. A novel MITO-Porter nanocarrier system enables targeted delivery of therapeutics into mitochondria, paving the way for new mitochondrial medicine and gene therapies.

More Related Videos

Author Spotlight: Bidirectional Mitochondrial Transfer between MSCs and Retinal Pigment Epithelium Cells &#8212; Pathways and In Vivo Challenges
06:50

Author Spotlight: Bidirectional Mitochondrial Transfer between MSCs and Retinal Pigment Epithelium Cells — Pathways and In Vivo Challenges

Published on: October 4, 2024

1.8K
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.7K

Related Experiment Videos

Last Updated: Mar 28, 2026

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis
08:15

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis

Published on: February 3, 2022

3.7K
Author Spotlight: Bidirectional Mitochondrial Transfer between MSCs and Retinal Pigment Epithelium Cells &#8212; Pathways and In Vivo Challenges
06:50

Author Spotlight: Bidirectional Mitochondrial Transfer between MSCs and Retinal Pigment Epithelium Cells — Pathways and In Vivo Challenges

Published on: October 4, 2024

1.8K
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.7K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Mitochondrial Biology

Background:

  • Mitochondrial dysfunction is implicated in numerous human diseases, including neurodegenerative disorders, ischemic heart disease, diabetes, and cancer.
  • Targeted mitochondrial therapy holds significant promise for treating these conditions.

Purpose of the Study:

  • To review the development of mitochondrial medicine and gene therapy using a novel drug delivery system (DDS).
  • To propose "mitochondrial DDS" as a key area for innovative drug development.

Main Methods:

  • Development of the MITO-Porter, a liposome-based nanocarrier for mitochondrial drug delivery.
  • Utilizing green fluorescence protein as a model macromolecule to confirm delivery into mitochondria in living cells via membrane fusion.

Main Results:

  • Demonstrated successful delivery of macromolecular cargo into mitochondria using the MITO-Porter system.
  • Confirmed the potential of the MITO-Porter for intracellular delivery to mitochondria in living cells.

Conclusions:

  • The MITO-Porter nanocarrier system facilitates macromolecule delivery into mitochondria.
  • Mitochondrial drug delivery systems (DDS) are crucial for advancing innovative therapies in mitochondrial medicine and gene therapy.